[Action of Parlodel on the preovulatory peak of estrogens and the ovulatory response of patients with abnormal ovulation and normal blood prolactin].
Bromocriptine, a dopamine agonist, is well known for its inhibitory action on prolactin secretion. Its action on other hypophyseal secretions, particularly on the gonadotrophins FSH and LH can indicate use of Parlodel as a stimulatory agent for induction of ovulation even in cases of normal prolactinemia. 129 normoprolactinemic patients with a defect of the preovulatory estrogen rise have been treated over a period of 3 months. 63% of the patients exhibited a positive response to bromocriptine, either because a pregnancy started or because preovulatory E1+E2 became normal. The rate of "responders" is increased among those patients who had conservation of spontaneous menses at the start of therapy. Conclusions of the study are that Parlodel has a place among treatments of ovulation defects. Its genuine efficacity must be confirmed by a controlled study against placebo and other confirmed treatments like antiestrogens.
D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology*; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000097:blood*; D004970:Estrone / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005498:Follicular Phase / Q000187:drug effects*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy; D007986:Luteinizing Hormone / Q000097:blood; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011388:Prolactin / Q000097:blood*; D013997:Time Factors
D004967:Estrogens; D004970:Estrone; D001971:Bromocriptine; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
Etude de l'action du Parlodel sur le pic préovulatoire d'estrogènes et la réponse ovulatoire des patientes ayant une anomalie de l'ovulation avec normoprolactinémie.